Moderna seeks FDA authorization for updated Covid-19 booster


Moderna said in a news release on Tuesday that it had filed its application to the US Food.


Drug Administration for emergency use permission of its modified Covid-19 vaccine booster for use in adults age 18 and older.


It would be given as a 50 microgram dose of this new bivalent vaccine formulation, which combines the original vaccination with one that targets the Omicron sublineages BA.4 and BA.5.

A phase 2/3 clinical trial for these boosters, according to the business, is currently under way.

Data from both human and mouse studies utilising a different booster that was modified to provide protection against the BA.1 strain of Omicron comprise the information they have sent to the FDA.

According to Stephane Bancel, Chief Executive Officer of Moderna, "We have worked closely with the FDA to ensure.

 Americans will have access to Moderna's updated, bivalent booster, which, if authorised, may offer higher, broader, and more durable protection against Covid-19 compared.

One day prior to the announcement, Pfizer and BioNTech claimed they had submitted their request for emergency use permission of its bivalent Covid-19 booster for use in people 12 and older.